首页> 美国卫生研究院文献>Blood >Transplantation: Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation
【2h】

Transplantation: Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation

机译:移植:供体激活KIR3DS1与无关的异基因造血干细胞移植中急性GVHD降低有关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The natural killer cell receptor KIR3DS1 is associated with improved outcome in malignancies, infections, and autoimmune diseases, but data for the impact of KIR3DS1 in HSCT are inconsistent. Using genomic DNA from the National Marrow Donor Program, we performed donor KIR genotyping for 1087 patients who received an unrelated hematopoietic stem cell transplantation. A total of 33% of donors were KIR3DS1+. Compared with KIR3DS1 donors, donor KIR3DS1 was associated with lower-grade II-IV acute graft-versus-host disease (GVHD; odds ratio = 0.71; 95% confidence interval, 0.55-0.92; P = .009), but not with relapse (hazard ratio = 0.97; 95% confidence interval, 0.73-1.29; P = .82). Furthermore, grade II-IV acute GVHD, overall mortality, and transplantation-related mortality all decreased as the number of copies of donor KIR3DS1 increased (P = .007, P = .03, and P = .02, respectively), with the lowest failure rate occurring among patients homozygous for donor KIR3DS1. Selection of donors with KIR3DS1 may decrease acute GVHD without compromising relapse-free survival, separating the graft-versus-tumor effect from unwanted GVHD.
机译:天然杀伤细胞受体KIR3DS1与恶性肿瘤,感染和自身免疫性疾病的预后改善相关,但KIR3DS1在HSCT中的影响数据不一致。使用来自国家骨髓捐献者计划的基因组DNA,我们对1087例接受了不相关造血干细胞移植的患者进行了捐献者KIR基因分型。共有33%的供体是KIR3DS1 + 。与KIR3DS1 -供体相比,供体KIR3DS1与低级II-IV急性移植物抗宿主病相关(GVHD;优势比= 0.71; 95%置信区间为0.55-0.92; P = .009),但没有复发(危险比= 0.97; 95%置信区间0.73-1.29; P = .82)。此外,随着供体KIR3DS1的拷贝数增加(分别为P = .007,P = .03和P = .02),II-IV级急性GVHD,总死亡率和与移植相关的死亡率均降低了。供体KIR3DS1纯合的患者中发生失败的比率最低。选择具有KIR3DS1的供体可能会降低急性GVHD,而不影响无复发生存率,从而将移植物抗肿瘤效果与不良GVHD分开。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号